These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15015709)

  • 1. Population pharmacokinetics of imipenem in burn patients.
    Dailly E; Kergueris MF; Pannier M; Jolliet P; Bourin M
    Fundam Clin Pharmacol; 2003 Dec; 17(6):645-50. PubMed ID: 15015709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem pharmacokinetics in patients with burns.
    Boucher BA; Hickerson WL; Kuhl DA; Bombassaro AM; Jaresko GS
    Clin Pharmacol Ther; 1990 Aug; 48(2):130-7. PubMed ID: 2379384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imipenem in burn patients: pharmacokinetic profile and PK/PD target attainment.
    Gomez DS; Sanches-Giraud C; Silva CV; Oliveira AM; da Silva JM; Gemperli R; Santos SR
    J Antibiot (Tokyo); 2015 Mar; 68(3):143-7. PubMed ID: 25227503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Study on the pharmacokinetics of Imipenem cilastatin in burn patients during the acute phase].
    Wang H; Peng Y; Xiao G
    Zhonghua Shao Shang Za Zhi; 2000 Dec; 16(6):349-51. PubMed ID: 11876899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of ceftazidime in burn patients.
    Dailly E; Pannier M; Jolliet P; Bourin M
    Br J Clin Pharmacol; 2003 Dec; 56(6):629-34. PubMed ID: 14616422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetic Modeling and Simulations of Imipenem in Burn Patients With and Without Continuous Venovenous Hemofiltration in the Military Health System.
    Por ED; Akers KS; Chung KK; Livezey JR; Selig DJ
    J Clin Pharmacol; 2021 Sep; 61(9):1182-1194. PubMed ID: 33811332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA; Hudson JQ; Hill DM; Swanson JM; Wood GC; Laizure SC; Arnold-Ross A; Hu ZY; Hickerson WL
    Pharmacotherapy; 2016 Dec; 36(12):1229-1237. PubMed ID: 27862103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vancomycin pharmacokinetics in patients with severe burn injuries.
    Dolton M; Xu H; Cheong E; Maitz P; Kennedy P; Gottlieb T; Buono E; McLachlan AJ
    Burns; 2010 Jun; 36(4):469-76. PubMed ID: 19875238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population pharmacokinetic approach to ceftazidime use in burn patients: influence of glomerular filtration, gender and mechanical ventilation.
    Conil JM; Georges B; Lavit M; Laguerre J; Samii K; Houin G; Saivin S
    Br J Clin Pharmacol; 2007 Jul; 64(1):27-35. PubMed ID: 17324245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
    Singlas E
    Presse Med; 1990 Apr; 19(13):598-605. PubMed ID: 2139939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of ceftazidime and cefepime in burn patients: the importance of age and creatinine clearance.
    Conil JM; Georges B; Lavit M; Seguin T; Tack I; Samii K; Chabanon G; Houin G; Saivin S
    Int J Clin Pharmacol Ther; 2007 Oct; 45(10):529-38. PubMed ID: 17966838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of arbekacin in burn patients.
    Kim JH; Lah HO; Yim DS
    Eur J Clin Pharmacol; 2008 Jun; 64(6):599-603. PubMed ID: 18320181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of delavirdine and N-delavirdine in HIV-infected individuals.
    Smith PF; Dicenzo R; Forrest A; Shelton M; Friedland G; Para M; Pollard R; Fischl M; DiFrancesco R; Morse GD
    Clin Pharmacokinet; 2005; 44(1):99-109. PubMed ID: 15634033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical evaluation of the postburn retention and the metabolism of Imipenem in the third space].
    Rong XZ; Bei CH; Huang XH; Li QH
    Zhonghua Shao Shang Za Zhi; 2003 Apr; 19(2):75-7. PubMed ID: 12812629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplification of Imipenem Dosing by Removal of Weight-Based Adjustments.
    Lala M; Brown M; Kantesaria B; Walker B; Paschke A; Rizk ML
    J Clin Pharmacol; 2019 May; 59(5):646-653. PubMed ID: 30536420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics and simulations of imipenem in critically ill patients undergoing continuous renal replacement therapy.
    Li S; Xie F
    Int J Antimicrob Agents; 2019 Jan; 53(1):98-105. PubMed ID: 30626495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid.
    van Hasselt JG; Rizk ML; Lala M; Chavez-Eng C; Visser SA; Kerbusch T; Danhof M; Rao G; van der Graaf PH
    Br J Clin Pharmacol; 2016 Jun; 81(6):1113-23. PubMed ID: 26852277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects of application of vancomycin in the early stage of patients with extremely severe burn].
    Zhu Z; Cao GW; Bao JJ; Hu ZH; Shen Z; Tao H; Cao B; Xu F
    Zhonghua Shao Shang Za Zhi; 2017 Apr; 33(4):206-210. PubMed ID: 28427133
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
    Chan CY; Lai KN; Lam AW; Li PK; Chung WW; French GL
    J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.